Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 30 Mar, 26 | GSK | Buy | USD 53.84 | USD 56.6 | USD 60.0 | 3 days | Closed |
5.29%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Specialty Medicines Momentum: FY25 Specialty Medicines revenue reached GBP 13.5 billion compared with GBP 11.5 billion in FY24, reflecting robust growth of 17% supported by Oncology and HIV portfolios
Core Earnings Growth: FY25 core EPS increased to 172.0 pence compared with 153.5 pence in FY24, reflecting growth of 12% supported by improved profitability and share buybacks
Increased R&D Investment Burden: FY25 R&D expenses increased to GBP 7.5 billion compared with GBP 6.3 billion in FY24, reflecting higher investment in pipeline development, impacting near-term profitability
Limited Vaccines Growth: FY25 Vaccines revenue was GBP 9.2 billion compared with GBP 9.0 billion in FY24, reflecting modest growth of only 2%, impacted by weaker U.S. demand
The company faces risks from pricing pressures and regulatory changes in key markets, ongoing generic competition in legacy portfolios, and execution risks associated with pipeline development and commercialization of new therapies
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 53.84 | 48.0 | 56.6 | 60.0 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Revenue Growth Driven by Specialty Medicines: During FY25, GSK reported total turnover of GBP 32.7 billion in FY25 compared with GBP 31.4 billion in FY24, reflecting growth of 4% at AER and 7% at CER, primarily driven by strong performance in Specialty Medicines. The growth trajectory was supported by continued demand across HIV, Oncology, and Respiratory, Immunology & Inflammation portfolios, offset partially by declines in General Medicines.
Specialty Medicines as Core Growth Engine: Specialty Medicines recorded revenue of GBP 13.5 billion in FY25 compared with GBP 11.5 billion in FY24, representing growth of 17%. Growth was led by Oncology, which increased significantly due to strong uptake of Jemperli and Ojjaara, alongside sustained expansion in HIV therapies such as Dovato, Cabenuva, and Apretude. Respiratory and immunology products, including Nucala and Benlysta, also contributed meaningfully to volume growth.
Vaccines Segment Shows Moderate Expansion: Vaccines revenue stood at GBP 9.2 billion in FY25 compared with GBP 9.0 billion in FY24, reflecting growth of 2%. The segment benefited from robust demand for Shingrix, meningitis vaccines, and RSV vaccine Arexvy in international markets. However, growth was partially offset by lower demand in the U.S. and declines in influenza vaccines due to competitive pressures.
General Medicines Under Pressure: General Medicines revenue declined marginally to GBP 10.0 billion in FY25 compared with GBP 10.1 billion in FY24, reflecting a 1% decline. While Trelegy demonstrated strong double-digit growth, this was offset by ongoing generic erosion and pricing pressure across other respiratory and established medicine portfolios.
Profitability Expansion and Margin Improvement: Total operating profit increased sharply to GBP 7.9 billion in FY25 compared with GBP 4.0 billion in FY24, reflecting growth exceeding 100%. This was primarily driven by lower legal expenses, reduced contingent consideration liabilities, and higher other operating income. Core operating profit rose to GBP 9.8 billion in FY25 compared with GBP 8.8 billion in FY24, indicating growth of 11%, supported by favorable product mix and operational efficiencies.
Earnings Growth and Shareholder Returns: Earnings per share increased significantly, with total EPS reaching 141.1 pence in FY25 compared with 69.0 pence in FY24, reflecting growth above 100%. Core EPS increased to 172.0 pence in FY25 compared with 153.5 pence in FY24, up 12%. Strong earnings enabled continued shareholder returns, including a dividend of 66 pence for FY25 and ongoing share buybacks.
Strong Cash Flow and Investment in R&D: Cash generated from operations increased to GBP 8.9 billion in FY25 compared with GBP 7.9 billion in FY24, while free cash flow rose to GBP 4.0 billion from GBP 2.9 billion. The company continued to invest in R&D, with multiple FDA approvals and pipeline advancements strengthening long-term growth prospects.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Buy’ recommendation has been given to GSK plc. (NYSE: GSK) at the closing market price of USD 53.84, as on Mar 27, 2026
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GSK GlaxoSmithKline PLC ADR |
-1.48 2.84% | 50.67 | 15.01 | 22.22 | 3.43 | 5.17 | 3.07 | 9.63 |
| LLY Eli Lilly and Company |
-13.43 1.21% | 1098.57 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
-5.81 2.48% | 228.39 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-4.74 2.14% | 216.49 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
-2.96 1.66% | 174.93 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on March 30, 2026. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned has been achieved and is subject to the factors discussed above.
Note 4: StockNextt reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2026 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
Australia